Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries ...

Twenty people died in Japan after receiving Tavneos, a rare disorder therapy developed by Amgen (AMGN), prompting its local partner Kissei (KSPHF) to urge healthcare professionals to exercise caution ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

Amgen named Thomas Dittrich, a former finance executive at the company, as its next chief financial officer. The biotechnology company said Tuesday that Dittrich will succeed Peter Griffith, who is ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BERLIN — In June, Amgen reported ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, ‌citing ⁠a lack of proven ...